Capstan Medical, a Santa Cruz, CA-based developer of robotic-enabled minimally invasive solutions to address heart valve disease, raised $110M in Series C funding.
The round was led by Eclipse, with participation from existing investors Yu Galaxy and Intuitive Ventures, and new investment from Gideon Strategic Partners.
The company intends to use the funds to further advance its robotics technology.
Founded in 2020 and led by Maggie Nixon, CEO, Capstan Medical is creating a new standard for minimally invasive, heart valve intervention. The company is developing a suite of new heart valve implants and a catheter-based robotic delivery platform.
Capstan has over 75 employees across engineering, operations, clinical, and regulatory.
FinSMEs
12/12/2024